2018


Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
2018/№1

Продолжительность двухкомпонентной антиагрегантной терапии у больных ишемической болезнью сердца после имплантации эндоваскулярного стента

Сумароков А. Б.1, Бурячковская Л. И.1, Ломакин Н. В.2, Доценко Ю. В.1, Учитель И. А.1, Тимофеева Л. А.2
1 ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава РФ, Москва
2 ФГБУ «Центральная клиническая больница с поликлиникой» УД Президента РФ, Москва

Ключевые слова: ишемическая болезнь сердца, антитромбоцитарная терапия, тромбоз, кровотечения, имплантация стента, длительность двухкомпонентной антитромбоцитарной терапии

DOI: 10.18087/cardio.2018.1.10081

Оптимальные сроки проведения длительной двухкомпонентной антитромбоцитарной терапии (ДАТ) после имплантации коронарного стента с лекарственным покрытием остаются неясными, так как у отдельных больных после завершения рекомендуемого курса ДАТ сохраняется риск развития тромботических осложнений, опасность тромбоза стента. В то же время существует реальная угроза кровотечений на фоне ДАТ. В обзорной работе представлены результаты клинических исследований по проблеме длительности ДАТ и данные мета-анализов. Рассмотрены вопросы продолжительности ДАТ в рекомендациях Американской ассоциации сердца и Американской коллегии кардиологов (AHA/ACC) 2016 года.
  1. Mauri L., Kerekiakes D., Yeh R. et al. For the DAPT study investigators. Twelve or 30 months of dual antiplatelet therapy after drugeluting stents. N Engl J Med 2014; V371: 2155–2166.
  2. Yeh R. A., Kereiakes D. J., Steg P. G. et al. on behalf of the DAPT Study Investigators., Benefit and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. JACC 2015;65 (20):2211–2221.
  3. Tsai T., Ho P., Xu S. et al. Increased risk of bleeding in patients onclopidogrel therapy after drug-eluting stent implantation. Insight from HMO Research Network-Stent registry (HMORN-Stent). Circ Cardiovasc Interv 2010;3:230–235.
  4. Kwok C., Bullick H., Rydung A. et al. Benefits and harms of extending the duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents: a meta-analysis. ScientificWorld J 2014; doi10.1155/2014/794978
  5. Gilard M., Barragan P., Noryani A. 6- versus 24‑month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistent to aspirin. The randomized, multicenter ITALIC trial. JACC 2015;65 (8):777–786.
  6. Schulz-Schupke S., Byrne R., ten Berg J. et al. On behalf of the Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 months dual anti-platelet therapy after drug-eluting stenting (ISAR-SAFE) trial investigators; ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6- vs 12‑months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;3:1252–1263.
  7. Colombo A., Chiefo A., Frasheri A. et al. Second-generation drugeluting stent implant-tation followed by 6-versus 12-month dual antiplatelet therapy. The SECURITY randomized clinical trial. JACC 2014;64 (20):2086–2097.
  8. Valgimigli M., Campo G., Monti M. et al. for the Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced therapy Intimal Hyperplasia Study (PRODIGY) investigators. Circulation 2012;125:2015–2016.
  9. Gwon H., Hahn J., Park K. et al. Six-month versus 12‑month dual antiplatelet therapy after implantation of drug-eluting stents. The Efficacy of Xience / Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505–513.
  10. Kim B., Hong M., Shin D. et al. for the RESET investigators. A new strategy for discontinuation and of dual antiplatelet therapy. The RESET trial (Real Safety and Efficacy of 3 month dual antiplatelet Therapy follow-ing Endeavor zotarolimus-eluting stent implantation). JACC 2012;60 (13):1340–1348.
  11. Feres F., Costa R., Abizaid A. et al. for the OPTIMIZE Trial Investigators. JAMA 2013;310 (23):2510–2522.
  12. Lee C. W., Ahn J.‑M., Park D.‑W. et al. Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation: A Randomized Controlled Trial. Circulation 2014;129:304–312.
  13. Collet J., Silvain J., Barthelemy O. et al. for the ARCTIC Investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC–Interruption): a randomized trial. Lancet 2014;384:1577–1585
  14. Park S., Park D., Kim Y. et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents (REAL/ZEST-LATE). N Engl J Med 2010;362:1374–1382.
  15. Belch J., Dormady J., Biasi G., CASPAR writing committee. Results of the randomized, placebo-controlled clopidogrel and acetiylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR trial). J Vasc Surgery 2010;52 (4):825–833.
  16. The SPS3 Investigators. Effect of clopidogrel added to aspirin in patients with recent lacunar stroke. NEJM 2012;367:817–825.
  17. Varenhorst C., Jensevik K., Jernberg T. et al. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. Eur Heart J 2014; 35:969–978.
  18. Hu T., Wang H. Duration of dual antiplatelet therapy and outcomes after left main percutaneous coronary intervention. Heart 2012;98 (2):E1–E319.
  19. Helft G., Steg P., Le Feuvre C. et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J 2016;21:365–374.
  20. Faxon D., Lawler E., Young M. et al. Prolonged clopidogrel use after bare metal and drug-eluting stent study. Circ Cardiovasc Interv 2012;5:372–380.
  21. Tanzilli G., Greco C., Pelliccia F. et al. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study). Am J Cardiol 2009;104(10):1357–1361.
  22. Song P., Hahn J., Kim D. et al. Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome. Eur J Intern Med 2015;26 (7):521–527.
  23. Manchuelle A., Delhaye C., Schurtz G. et al. Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: determinants and impact on prognosis. Archives Cardiovasc Disease 2015;108 (4):235–243.
  24. Kotani J., Ikari Y., Kyo E. et al. on behalf of the J-PMC investigators. Consideration of dual anti-platelet therapy duration after drug-stent implantation in japanese population: a five-year follow-up after sirolimus-eluting stent implantation. Int Med 2013;52:703–711.
  25. Ho Р., Fihn S., Wang L. et al. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome Am Heart J 2007;152 (5):846–851.
  26. Doctorova M., Motowska S. Clinical review: bleeding – a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management. Critical Care 2013;17 (5):239–251.
  27. Gouya G., Arrich J., Woltz M. et al. Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients with Vascular Diseases. A Systemic Review and Meta-Analysis. Stroke 2014;45:492–503.
  28. Campo G., Tebaldi M., Vranchx P. et al. Short versus long-term duration of dual antiplatelet therapy in patients treated for in stent restenosis. A PRODIGY trial substudy (prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia). JACC 2014;63 (6):506–512.
  29. Bangalore S., Amorosa N., Fusaro M. et al. Outcomes with various drug-eluting or bare metal stents in patients with ST-segmentelevation myocardial infarction. A mixed treatment comparison analysis of trial level data from 34068 patient-years of follow-up from randomized trials. Circ Cardiovasc Interv 2013;6:378–390.
  30. Urban P., Meredith I., Abizaid A. et al. for the LEEDERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. NEJM 2015;373 (21):2038–2047.
  31. Costa F., Vranckx P., Leonardi S. et al. Impact of clinical presentation on ischemic and bleeding outcomes in patients receiving 6- or 24‑month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODYGY (prolonging dual-antiplatelet treatment after grading stent-induced intimal hyperplasia) trial. Eur Heart J 2015;36:1242–1251.
  32. Navarese E., Andreotti F., Schulze V. et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents: meta-analysis of randomized trials. BMJ 2015;350: h1618.
  33. Elmariah S., Mauri L., Doros G. et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 2015;385:792–798.
  34. Bullick H., Kwok C., Ryding A., Loke Y. Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated metaanalysis with direct and adjusted indirect comparison of randomized control trials. Int J Cardiol 2015;181:331–339.
  35. Guestino G., Baber U., Sartori S. et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation. A systematic review and meta-analysis of randomized controlled trials. JACC 2015; 65:1298–1310.
  36. Panditt A., Giri S., Hakim F., Fortuin F. Shorter (≤6 months) versus longer (≥12 months) duration of dual antiplatelet therapy after drug eluting stents: A meta-analysis of randomized cliniсal trials. Catheterization and cardiovascular interventions. Catheter Cardiovasc Interv 2015;85:34–40.
  37. Cassese S., Byrne R., Tada T. et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary intervention in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 2012;33:3078–3087.
  38. El-Hayek G., Messerli F., Bangalore S. et al. Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. Am J Cardiol 2014;114:236–242
  39. Verdoia M., Schaefer A., Barbieri L. et al. Optimal duration of dual antiplatelet therapy after DES implantation: a meta-analysis of 11 randomized trials. Angiology 2016;67:224–238.
  40. Valgimigli M., Park S., Kim H. et al. Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials. Int J Cardiol 2013;168:2579–2587.
  41. Costa F., Adamo M., Ariotti S. et al. Impact of greater than 12‑month dual antiplatelet therapy duration on mortality. Int J Cardiol 2015;36:179–181.
  42. Palacio S., Hart R., Pearce L., Anderson D. et al. Effect of addition of clopidogrel to aspirin on stroke incidence: Meta-analysis of randomized trials. Int J Stroke 2015;10:686–691.
  43. Liou K., Nagaraja V., Jepson N. et al. Optimal duration of dual antiplatelet therapy following drug-eluting stents implantation: A meta-analysis of 7 randomized controlled trials. Int J Cardiol 2015;201:578–580.
  44. Pang S., Shi S., Zhang Y. et al. The impact of dual antiplatelet therapy on primary composite endpoints after drug-eluting stent implantation: A meta-analysis of 10 randomized trials. Int J Cardiol 2016;202:504–506.
  45. Palmerini T., Benedetto U., Bacchi-Reggiani L. et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomized trials. Lancet 2015;385(9985):2371–2382.
  46. FDA: Drug Safety Communications. On 14 november 2015. FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death. Safety Annoucement. FDA: Drug Safety Communications. On 14 November 2015. FDA.
  47. Spenser F., Prasad M., Vandvik P. et al. Long-term use of tikagrelor in patients with prior myocardial infarction. NEJMed 2015;372 (19):1791–1800.
  48. Levine G., Bates E. R., Bittl J. A. et al. 2016 ACC/AHA Guideline Focused Update on Duration of Duration of Dual Antiplatelet Therapy in Patients With Coronary Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016;134 (10):e123–55. doi: 10.1161/CIR.0000000000000404.
  49. Montalescott G., Brieger D., Dalby A. et al. Duration of Dual antiplatelet therapy after coronary stenting. A review of the evidence. JACC 2015;66 (7):832–847.
  50. Yeh R. W. Individualyzing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis from the DAPT Study. Presented at: AHA scientific Sessions; November 10, 2015, Orlando, Fl. Доступно на сайте: www.acc.org/latest-in…/clinical/dapt-study. Доступно на сайте: www.fda.gov/Drugs/DrugsSafety/ucm471286.htm
Сумароков А. Б., Бурячковская Л. И., Ломакин Н. В., Доценко Ю. В., Учитель И. А., Тимофеева Л. А. Продолжительность двухкомпонентной антиагрегантной терапии у больных ишемической болезнью сердца после имплантации эндоваскулярного стента. Кардиология. 2018;58(1):41–52.

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En